RITONAVIR INHIBITS PRASUGREL IN VITRO BIOACTIVATION: A POTENTIAL PHARMACOKINETIC INTERACTION

被引：0
|
作者：
Ancrenaz, V
Daali, Y.
Samer, C.
Bosilkovska, M.
Dayer, P.
Desmeules, J.
机构：
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：150 / 150
页数：1
相关论文
共 50 条
  • [1] RITONAVIR INHIBITS PRASUGREL IN VITRO BIOACTIVATION: A POTENTIAL PHARMACOKINETIC DRUG-DRUG INTERACTION
    Ancrenaz, V.
    Daali, Y.
    Samer, C.
    Dayer, P.
    Desmeules, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S56 - S56
  • [2] Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients
    Daali, Youssef
    Ancrenaz, Virginie
    Bosilkovska, Marija
    Dayer, Pierre
    Desmeules, Jules
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (11): : 1584 - 1589
  • [3] Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
    Ancrenaz, Virginie
    Deglon, Julien
    Samer, Caroline
    Staub, Christian
    Dayer, Pierre
    Daali, Youssef
    Desmeules, Jules
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 112 (02) : 132 - 137
  • [4] Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
    Itkonen, Matti K.
    Tornio, Aleksi
    Lapatto-Reiniluoto, Outi
    Neuvonen, Mikko
    Neuvonen, Pertti J.
    Niemi, Mikko
    Backman, Janne T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (01) : 219 - 228
  • [5] Pharmacokinetic interaction between ritonavir and clarithromycin
    Ouellet, D
    Hsu, A
    Granneman, GR
    Carlson, G
    Cavanaugh, J
    Guenther, H
    Leonard, JM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) : 355 - 362
  • [6] CLOPIDOGREL MARKEDLY INCREASES DASABUVIR EXPOSURE, AND RITONAVIR INHIBITS THE BIOACTIVATION OF CLOPIDOGREL
    Itkonen, M. K.
    Tornio, A.
    Lapatto-Reiniluoto, O.
    Neuvonen, M.
    Neuvonen, P. J.
    Niemi, M.
    Backman, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 3 - 3
  • [7] Evaluation of the pharmacokinetic interaction between ritonavir and didanosine
    Cato, A
    Qian, J
    Carothers, L
    Carlson, G
    Locke, C
    Hsu, A
    Granneman, R
    Leonard, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI59 - PI59
  • [8] Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir
    Sale, M
    Sadler, BM
    Stein, DS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 746 - 754
  • [9] The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers
    Liddy, Anne Marie
    McLaughlin, Gavin
    Schmitz, Susanne
    D'Arcy, Deirdre M.
    Barry, Michael G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (10) : 2235 - 2241
  • [10] Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir
    Pham, Paul A.
    Flexner, Charles
    Parsons, Teresa
    Vasist, Lakshmi
    Fuchs, Edward
    Carson, Kathryn
    Agarwala, Sangeeta
    Barditch-Crovo, Patricia
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (02) : 201 - 205
12345